M&A Deal Summary |
|
|---|---|
| Date | 2014-04-04 |
| Target | Ranbaxy Laboratories |
| Sector | Life Science |
| Buyer(s) | Sun Pharmaceuticals Industries |
| Sellers(s) | Daiichi Sankyo |
| Deal Type | Divestiture |
| Deal Value | 4.0B USD |
| Advisor(s) | ICICI Securities Ltd. (Financial) Luthra & Luthra Amarchand & Mangaldas & Suresh A. Shroff & Co. (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1983 |
| Sector | Life Science |
| Employees | 37,000 |
| Revenue | 384.3B INR (2022) |
Sun Pharmaceuticals Industries is a specialty generic pharmaceutical company. Products are sold through drug stores, mass merchants, grocery stores and gift/specialty stores. Sun Pharmaceuticals Industries was founded in 1983 and is based in Mumbai, India.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 14 |
| Sector (Life Science) | 4 of 9 |
| Type (Divestiture) | 1 of 2 |
| Country (India) | 4 of 4 |
| Year (2014) | 1 of 2 |
| Size (of disclosed) | 1 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2012-12-20 |
DUSA Pharmaceuticals
Wilmington, Massachusetts, United States DUSA Pharmaceuticals, Inc.® is a fully integrated specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform used in conjunction with it’s proprietary light source, the BLU-U® Blue Light Photodynamic Therapy Illuminator. |
Buy | $230M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-07-16 |
Pharmalucence
Bedford, Massachusetts, United States Pharmalucence, Inc.manufacturer of human injectable pharmaceuticals.We provide contract and private label formulation development and manufacturing services of parenteral products in either liquid or lyophilized form. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1899 |
| Sector | Life Science |
| Employees | 16,458 |
| Revenue | 1,044.9B JPY (2022) |
Daiichi Sankyo established through merger of Sankyo and Daiichi pharmaceutical. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals. Daiichi Sankyo was incorporated in 1899 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 4 |
| Sector (Life Science) | 1 of 3 |
| Type (Divestiture) | 1 of 4 |
| Country (India) | 1 of 1 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-28 |
Plexxikon
Berkeley, California, United States Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease. |
Buy | $805M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-09-28 |
Ambit Biosciences
San Diego, California, United States Ambit Biosciences Corp. is a biotechnology company focused on oncology; provides drug discovery services to the pharmaceutical industry. |
Buy | $315M |
